Prospective characterisation of non-malignant, paediatric lymphoproliferative disease

Affiliations

Comment

Troy R Torgerson. Lancet Haematol. 2024 Feb.

. 2024 Feb;11(2):e87-e88.

doi: 10.1016/S2352-3026(24)00002-4.

¹ Allen Institute for Immunology, Seattle, WA 98109, USA. Electronic address: troy.torgerson@alleninstitute.org.

No abstract available

Conflict of interest statement

I have received consulting fees from Pharming Healthcare outside the submitted work.

Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.
Hägele P, Staus P, Scheible R, Uhlmann A, Heeg M, Klemann C, Maccari ME, Ritterbusch H, Armstrong M, Cutcutache I, Elliott KS, von Bernuth H, Leahy TR, Leyh J, Holzinger D, Lehmberg K, Svec P, Masjosthusmann K, Hambleton S, Jakob M, Sparber-Sauer M, Kager L, Puzik A, Wolkewitz M, Lorenz MR, Schwarz K, Speckmann C, Rensing-Ehl A, Ehl S; ALPID study group. Hägele P, et al. Lancet Haematol. 2024 Feb;11(2):e114-e126. doi: 10.1016/S2352-3026(23)00362-9. Lancet Haematol. 2024. PMID: 38302222